z-logo
open-access-imgOpen Access
Utilization of curcumine and nanocurcumine compounds in cancer therapy
Author(s) -
Vajiheh Alinezhad,
Heshmatollah Alinezhad,
Ramin Ataee,
Amin Ataie
Publication year - 2017
Publication title -
pharmaceutical and biomedical research
Language(s) - English
Resource type - Journals
eISSN - 2423-4494
pISSN - 2423-4486
DOI - 10.29252/pbr.3.3.1
Subject(s) - cancer therapy , cancer , medicine
*Corresponding author: raminataee1349@gmail.com Curcumin is a polyphenol extracted from the Curcuma plant. Curcumin has been used widely in ayurvedic medicine for centuries; it has a variety of biological properties including anti-oxidant, analgesic, anti-inflammatory and antiseptic activity. Curcumin has shown anti-cancer activities through variety of biological pathways engaged in mutagenesis, oncogene expression, cell cycle regulation, apoptosis, tumorigenesis and metastasis. Curcumin has proved anti-proliferative effect in many cancers, and is an inhibitor of the transcription factor NF-κB and downstream gene products (including c-myc, Bcl-2, COX-2, NOS, Cyclin D1, TNF-α, interleukins and MMP-9). Furthermore, curcumin affects a variety of growth factor receptors and cell adhesion molecules involved in tumor growth, angiogenesis and metastasis. However, a limiting factor is its extremely low bioavailability which hinders its use as therapeutic agent. Therefore, many technologies have been developed to overcome this limitation. We summarize to develop curcumin delivery aims and increase solubility for improving curcumin bioavailability and anticancer potential for therapy. Article history: Received: Aug 24, 2017 Accepted: Sep 28, 2017

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom